BLRX vs. LTRN, BYSI, SPRO, MGTA, HCWB, NXTC, NRXP, BCEL, SNSE, and LFVN
Should you be buying BioLineRx stock or one of its competitors? The main competitors of BioLineRx include Lantern Pharma (LTRN), BeyondSpring (BYSI), Spero Therapeutics (SPRO), Magenta Therapeutics (MGTA), HCW Biologics (HCWB), NextCure (NXTC), NRx Pharmaceuticals (NRXP), Atreca (BCEL), Sensei Biotherapeutics (SNSE), and LifeVantage (LFVN). These companies are all part of the "pharmaceutical preparations" industry.
BioLineRx vs.
BioLineRx (NASDAQ:BLRX) and Lantern Pharma (NASDAQ:LTRN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
BioLineRx received 485 more outperform votes than Lantern Pharma when rated by MarketBeat users. However, 85.71% of users gave Lantern Pharma an outperform vote while only 74.07% of users gave BioLineRx an outperform vote.
BioLineRx has a beta of 1.82, indicating that its stock price is 82% more volatile than the S&P 500. Comparatively, Lantern Pharma has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
In the previous week, Lantern Pharma had 8 more articles in the media than BioLineRx. MarketBeat recorded 11 mentions for Lantern Pharma and 3 mentions for BioLineRx. Lantern Pharma's average media sentiment score of 0.35 beat BioLineRx's score of 0.08 indicating that Lantern Pharma is being referred to more favorably in the news media.
BioLineRx presently has a consensus price target of $6.00, indicating a potential upside of 689.47%. Lantern Pharma has a consensus price target of $11.00, indicating a potential upside of 154.04%. Given BioLineRx's higher probable upside, equities research analysts plainly believe BioLineRx is more favorable than Lantern Pharma.
Lantern Pharma is trading at a lower price-to-earnings ratio than BioLineRx, indicating that it is currently the more affordable of the two stocks.
18.2% of BioLineRx shares are held by institutional investors. Comparatively, 21.6% of Lantern Pharma shares are held by institutional investors. 1.1% of BioLineRx shares are held by company insiders. Comparatively, 23.0% of Lantern Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Lantern Pharma's return on equity of -23.07% beat BioLineRx's return on equity.
Summary
Lantern Pharma beats BioLineRx on 9 of the 14 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioLineRx Competitors List
